Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00797888 · ClinicalTrials.gov registry record · NA
Bronx A1c: Bring it Down for Health
A NA study of Type 2 Diabetes, sponsored by Albert Einstein College of Medicine.
- Completed
- Registry status
- NA
- Development phase
- 941
- Enrollment target
- 1
- Study location
NCT00797888: Completed NA study of Type 2 Diabetes, sponsored by Albert Einstein College of Medicine.
NCT00797888 is a NA study of Type 2 Diabetes that has completed, run by Albert Einstein College of Medicine. The registered enrollment target is 941 participants, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (76% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00797888, a NA study of Type 2 Diabetes, has completed, sponsored by Albert Einstein College of Medicine.
- COMPLETED
- Registry status
- NA
- Development phase
- 941 participants
- Enrollment target
- 1
- Study location
Study Summary
To address and reduce population-attributable risk due to elevated HbA1c, the New York City Department of Health and Mental Hygiene (DOHMH) developed an innovative HbA1c registry, which requires all major laboratories to report HbA1c results electronically. We propose to utilize this registry to conduct a randomized controlled trial addressing the following specific aims: 1) to evaluate the incremental effect of a tiered and tailored, patient-centered telephone intervention, in English and Spanish, on the mean HbA1c levels beyond that achieved with print materials mailed to patients and providers by the DOHMH registry intervention; 2) determine what patient demographic and psychosocial factors mediate the effect of the interventions; and 3) provide estimates of implementation costs of the tiered, tailored telephone intervention for comparison with the print intervention. The study outcome will be change in HbA1c values from the registry records from baseline to one-year post-randomization. A total of 941 individuals with diabetes will be needed to provide 83% power to detect a statistically significant difference (p\<0.05) between groups of at least 0.3% in absolute HbA1c. Intervention cost data will be evaluated for translation of findings and scalability. At study end, we will know the extent to which this intervention will improve metabolic control in a low-income, multi-ethnic sample who are part of the DOHMH HbA1c registry in the South Bronx, New York. These findings will inform public health policies and practices in New York City, as well as other urban areas throughout the nation.
Conditions Studied
Interventions
- BEHAVIORAL telephonic
Study Locations (1)
New York
- New York City Department of Health & Mental Hygiene - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 941 participants |
| Start Date | 2008-09 |
| Est. Completion | 2012-06 |
| Phase | NA |
What the finished NCT00797888 record still lists
NCT00797888 is an interventional study that assigns participants to a tested intervention. The registered 941 participants enrollment target is mid-sized for trials with a published cap, below the 3,921-participant average among 327 other Type 2 Diabetes trials with a reported enrollment target (76% lower).
The record links to 1 condition, with Type 2 Diabetes appearing as the primary indexed condition, and to 1 intervention - of which telephonic is the first listed.
NCT00797888 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT00797888 about?
NCT00797888 is a clinical study titled "Bronx A1c: Bring it Down for Health". To address and reduce population-attributable risk due to elevated HbA1c, the New York City Department of Health and Mental Hygiene (DOHMH) developed an innovative HbA1c registry, which requires all major laboratories to report HbA1c results electronically. We propose to utilize this registry to con...
What is the current status of trial NCT00797888?
This trial is currently completed. It is a NA study. The enrollment target is 941 participants. The study started on 2008-09. Estimated completion is 2012-06.
What conditions does trial NCT00797888 study?
This clinical trial studies the following conditions: Type 2 Diabetes.
What interventions are being tested in trial NCT00797888?
The interventions under investigation include: telephonic (BEHAVIORAL).
Who is sponsoring clinical trial NCT00797888?
This trial is sponsored by Albert Einstein College of Medicine, which has 175 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00797888 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Type 2 Diabetes
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00797888's enrollment target sits among peer trials
941 28th of 327 higher than 300 of 327 other Type 2 Diabetes trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Type 2 Diabetes trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Enhancing Telemedicine for T2D
RECRUITING · NA
-
Sleep and Glycemic Control in Type 2 Diabetes Adolescents
RECRUITING · NA
-
Enhancing Preventative Health Behaviors Among Emergency Department Hyperglycemic Patients
RECRUITING · NA
-
Ultrasound Effects on Glycemic Control in T2DM
RECRUITING · NA
-
A Randomized Double-Blinded and Placebo-Controlled Trial to Assess the Efficacy of Biophoton Therapy to Treat Type 2 Diabetes
RECRUITING · NA
-
High Fructose Diet, the Gut Microbiome, and Metabolic Health
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06808334 · 942 participants
CLAiR Pivotal Study
- NCT07190209 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype
- NCT07190222 · 942 participants · Phase 3
Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD), Characterized by an Eosinophilic Phenotype
- NCT03075696 · 940 participants · Phase 1
A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-cell Non-hodgkin's Lymphoma
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia